Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)

Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study)

We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). Eligible patients aged ≥6 months to

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer (1990) 2017-09, Vol.83, p.177-184
Hauptverfasser: Chisholm, Julia C., Merks, Johannes H.M., Casanova, Michela, Bisogno, Gianni, Orbach, Daniel, Gentet, Jean-Claude, Thomassin-Defachelles, Anne-Sophie, Chastagner, Pascal, Lowis, Stephen, Ronghe, Milind, McHugh, Kieran, van Rijn, Rick R., Hilton, Magalie, Bachir, Jeanette, Fürst-Recktenwald, Sabine, Geoerger, Birgit, Oberlin, Odile
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adolescents
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
Bevacizumab - adverse effects
Bevacizumab - therapeutic use
Cancer
Chemotherapy
Child
Child, Preschool
Children
Clinical trials
Confidence intervals
Cyclophosphamide
Disease-Free Survival
Female
Humans
Immunotherapy
Induction Chemotherapy - methods
Infant
Maintenance Chemotherapy - methods
Male
Metastases
Metastasis
Metastatic soft tissue sarcoma
Monoclonal antibodies
NRSTS
Paediatrics
Patients
Radiation therapy
Randomization
Rhabdomyosarcoma
RMS
Sarcoma
Sarcoma - drug therapy
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - pathology
Soft tissue sarcoma
Statistical analysis
Surgery
Targeted cancer therapy
Teenagers
Toxicity
Vinorelbine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). Eligible patients aged ≥6 months to
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2017.06.015